Platelet turnover in advanced diabetes
- PMID: 8013530
- DOI: 10.1111/j.1365-2362.1994.tb02424.x
Platelet turnover in advanced diabetes
Abstract
There is considerable information to indicate that when there is vessel injury, platelets can play a major role in the development of atherosclerosis and its thromboembolic complications in the non-diabetic population. Diabetes is a disease associated with an increased risk of vascular complications, but the nature of this association is unclear. Platelets from diabetic humans and animals are hypersensitive to agonists in vitro, but it is unclear if this hypersensitivity persists in vivo. Platelets survival and turnover in the circulation have been used as indicators of platelet behaviour in vivo, but platelet survival measurements do not necessarily correlate with platelet sensitivity in vitro and these measurements may be too insensitive to reflect platelet turnover on injured vessels or in thrombi, unless there is extensive vascular disease. Studies in rats and rabbits indicate that diabetes causes increased platelet interaction with experimentally-injured vessels and accumulation in thrombi. It is unclear, however, whether this altered behaviour of platelets at the injured vessel surface reflects changes in the platelets or in the vessel wall and whether it contributes to the increased risk for vascular complications in diabetic patients.
Similar articles
-
Platelets, vascular disease, and diabetes mellitus.Can J Physiol Pharmacol. 1994 Mar;72(3):295-303. doi: 10.1139/y94-045. Can J Physiol Pharmacol. 1994. PMID: 8069776 Review.
-
Increased platelet, but unaltered fibrinogen, accumulation in experimental thrombi in alloxan-induced diabetic rabbits.Exp Mol Pathol. 1992 Oct;57(2):134-44. doi: 10.1016/0014-4800(92)90005-v. Exp Mol Pathol. 1992. PMID: 1426157
-
Platelets and diabetic vascular disease.Diabete Metab. 1983 Dec;9(4):306-12. Diabete Metab. 1983. PMID: 6230270 Review.
-
Platelet abnormalities in diabetes mellitus.Diabetes. 1992 Oct;41 Suppl 2:26-31. doi: 10.2337/diab.41.2.s26. Diabetes. 1992. PMID: 1526332 Review.
-
Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus.Curr Pharm Des. 2005;11(18):2331-65. doi: 10.2174/1381612054367337. Curr Pharm Des. 2005. PMID: 16022671 Review.
Cited by
-
Association of Long-term Use of Low-Dose Aspirin as Chemoprevention With Risk of Lung Cancer.JAMA Netw Open. 2019 Mar 1;2(3):e190185. doi: 10.1001/jamanetworkopen.2019.0185. JAMA Netw Open. 2019. PMID: 30821825 Free PMC article.
-
Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements.Nat Rev Cardiol. 2009 Apr;6(4):273-82. doi: 10.1038/nrcardio.2009.10. Nat Rev Cardiol. 2009. PMID: 19352331 Review.
-
Inhibition of pyruvate dehydrogenase complex activity by 3-bromopyruvate affects blood platelets responses in type 2 diabetes.Pharmacol Rep. 2020 Feb;72(1):225-237. doi: 10.1007/s43440-019-00005-0. Epub 2020 Jan 10. Pharmacol Rep. 2020. PMID: 32016856
-
Effect of glucose or fat challenge on aspirin resistance in diabetes.Int J Endocrinol. 2010;2010:820876. doi: 10.1155/2010/820876. Epub 2011 Jan 26. Int J Endocrinol. 2010. PMID: 21318184 Free PMC article.
-
Aspirin resistance: current status and role of tailored therapy.Clin Cardiol. 2012 Nov;35(11):673-81. doi: 10.1002/clc.22031. Epub 2012 Jun 27. Clin Cardiol. 2012. PMID: 22740110 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical